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Abstract
Dengue is the most prevalent emerging mosquito-borne viral disease, affecting 
more than 40% of the human population worldwide. Many symptomatic dengue 
virus (DENV) infections result in a relatively benign disease course known as 
dengue fever (DF). However, a small proportion of patients develop severe clinical 
manifestations, englobed in two main categories known as dengue hemorrhagic 
fever (DHF) and dengue shock syndrome (DSS). Secondary infection with any of 
the four dengue virus serotypes (DENV1, -2, -3, and -4) is a risk factor to develop 
severe forms of dengue disease. DSS is primarily characterized by sudden and 
abrupt endothelial dysfunction, resulting in vascular leak and organ impairment, 
which may progress to hypovolemic shock and death. Severe DENV disease (DHF/
DSS) is thought to follow a complex relationship between distinct immunopatho-
genic processes involving host and viral factors, such as the serotype cross-reactive 
antibody-dependent enhancement (ADE), the activation of T cells and complement 
pathways, the phenomenon of the cytokine storm, and the newly described viral 
toxin activity of the nonstructural protein 1 (NS1), which together play critical 
roles in inducing vascular leak and virus pathogenesis. In this chapter that is divided 
in two parts, we will outline the recent advances in our understanding of DENV 
pathogenesis, highlighting key viral-host interactions and discussing how these 
interactions may contribute to DENV immunopathology and the development of 
vascular leak, a hallmark of severe dengue. Part I will address the general features of 
the DENV complex, including the virus structure and genome, epidemiology, and 
clinical outcomes, followed by an updated review of the literature describing the 
host innate immune strategies as well as the viral mechanisms acting against and in 
favor of the DENV replication cycle and infection.
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1. Introduction
Dengue is still considered the most prevalent viral disease transmitted by 
arthropod mosquitoes (e.g., Aedes mosquitoes), with 50–100 million dengue infec-
tions occurring annually, and a global incidence of 30-fold increase observed over 
the past 50 years [1–3]. Most of the dengue infections with any of the four dengue 
virus (DENV) serotypes [1–4] result in inapparent, subclinical illness, or mild 
disease symptoms known as dengue fever (DF). However, some DENV infections 
can potentially evolve into more severe and fatal disease outcomes known as dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [2]. DHF and DSS are 
mainly characterized by low numbers of circulating platelets (thrombocytopenia) 
associated with hemorrhagic manifestations and increased vascular permeability 
associated with endothelium hyperpermeability, resulting in plasma leakage, low 
blood pressure, and shock that can lead to death [2]. DENV infections frequently 
occur in the context of preexisting immunity, where the immune responses to prior 
DENV infection play an important role in determining the outcome of dengue 
epidemics and disease severity via antibody-dependent enhancement (ADE) and 
potentially harmful T cell responses in an original antigenic sin-dependent manner 
[4–8]. Both mechanisms lead to increased activation of immune cells, resulting in 
exacerbated immune responses or cytokine storms that cause endothelium dysfunc-
tion and vascular leak [9, 10]. Collectively, these host immunological responses are 
thought to create a physiological environment that promotes vascular permeability. 
However, the exact mechanisms underlying the capillary leak are probably more 
complex than a cytokine storm, and the risk of severe disease upon DENV infection 
cannot be explained completely by a misdirected host immune response to a prior 
infecting serotype; rather, disease severity appears to be determined by a combina-
tion of multiple host and viral factors leading to favorable and unfavorable interac-
tions that regulate viral pathogenesis.
Despite considerable advances in understanding the immunological mechanisms 
activated during DENV infection, the pathogenic mechanisms underlying the 
alterations in permeability of the microvasculature remain unclear. The absence of 
a good animal model faithful to human disease and the limited knowledge of the 
factors regulating the intrinsic microvascular permeability in health have seriously 
hampered the research progress in this area. However, in the last decades, signifi-
cant progress has been made regarding viral and host cellular components involved 
in DENV infection and disease [8]. The nonstructural protein 1 (NS1) protein of 
DENV and other related flaviviruses has been described as an essential cofactor in 
virus replication and assembly [11, 12]. Interestingly, the secreted form of NS1 is 
also implicated in immune evasion strategies via interaction with several proteins 
of the complement pathways that protect the virus-infected cells from the immune 
system processing [12–14]. Contrary, NS1 and anti-NS1 antibodies can also mediate 
complement activation that may alter capillary permeability [15]. Additionally, the 
soluble NS1 from DENV can interact with the surface of endothelial cells, immune 
cells, and platelets to cause endothelial barrier dysfunction and vascular leakage, 
and potentially hampers the coagulation cascades leading to hemorrhagic manifesta-
tions during DENV infection. These phenomena occur via activation of endothelial-
intrinsic mechanisms leading to the disruption of the EGL and the integrity of the 
cell-to-cell contacts and/or induction of pro-inflammatory cytokines, chemokines, 
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and proteases via the TLR4 activation of monocytes/macrophages that may act 
also on endothelial cells leading to endothelial hyperpermeability and vascular 
leak [16–22]. Furthermore, NS1 is highly immunogenic and conserved between 
the Flavivirus genus; thus, NS1 from other flaviviruses have been also reported 
to activate endothelial-intrinsic mechanisms causing vascular leakage in a tissue-
dependent manner that mimics each flavivirus disease pathophysiology [17, 23–25]. 
Additionally, NS1 immunization using mouse models and DENV vaccination or 
natural DENV infection in humans can elicit antibodies’ responses that have been 
implicated in the contradictory roles of protection and pathogenesis in the infected 
host [25–42]. Today, no specific and effective vaccine candidate, antiviral therapy, 
or anti-inflammatory therapeutics have been licensed to combat dengue disease. An 
effective dengue vaccine is surely needed to avert the millions of dengue cases that 
occur around the world, continuously threatening with fatal outcomes. For decades, 
numerous experts in infectious diseases including clinicians, epidemiologists, basic 
scientists, and vaccine and drug developers have been trying to elucidate the ulti-
mate mechanism of DENV pathogenesis leading to severe dengue disease. The NS1 
protein of flaviviruses constitutes a unique “viral toxin” that seems to connect many 
of the already described DENV immunopathogenic mechanisms leading to severe 
dengue disease; thus, NS1 might represent the corner piece that completes the 
elusive dengue pathogenesis puzzle. Therapeutic approaches and vaccine develop-
ment targeting NS1 may provide different opportunities for the future defeating of 
the global dengue disease. A better understanding of DENV immunopathogenesis 
will assist not only in the development of therapeutic interventions but also in the 
understanding of dengue vaccine efficacy or vaccine adverse events. This chapter 
briefly summaries the key clinical, virological, and epidemiological facts about 
DENV innate and humoral responses and gives an extensive update of insights 
about the viral and host factors that contribute to DENV pathogenesis leading to the 
development of severe dengue manifestations during DENV infection.
2. Dengue virus features: genomic organization, structure, and life cycle
Dengue virus (DENV) belongs to the genus Flavivirus (family Flaviviridae), 
a group of small (50-nm virion diameter) viruses containing a single-positive-
stranded RNA genome [5′ capped, not 3′ poly(A) tail] which encodes for three 
structural proteins: capsid (C), membrane (M), and envelope (E) and seven 
nonstructural (NS) proteins named NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 
(Figure 1A, B) [43]. The DENV group is comprised of four evolutionary distinct 
but antigenically and genetically related viruses better known as DENV serotypes 
−1, −2, −3, and −4 (DENV-1-4), [44, 45]. These four established serotypes (DENV 
1–4) share a high degree of sequence similarity between the genomes (~65–70%) 
[46], with average sequence identity between proteomes of 39–79% [47]. DENV 
is transmitted to humans by Aedes mosquitoes, mainly Aedes aegypti. However, the 
global distribution of Aedes albopictus (the Asian tiger mosquito), considered a 
secondary vector for DENV transmission, is changing rapidly and it is now becom-
ing an increasingly important vector and a common cause of epidemics in Aedes 
aegypti-free countries [48–50]. Human-to-mosquito transmission occurs once the 
mosquito takes a blood meal from DENV-infected people who are viremic, which is 
normally up to 2 days before someone shows symptoms of the illness or up to 2 days 
after the fever has resolved. High viremia and high fever in patients are positively 
associated with a high rate of DENV transmission from humans to mosquitoes [51]. 
After feeding on a DENV-infected person, depending mainly on temperature, the 
virus rapidly replicates in the mosquito’s midgut, and within an average of 5.9 days, 
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it disseminates to secondary tissues, including the salivary glands where the virus 
can be transmitted to the new host (extrinsic incubation period) [52]. Once infec-
tious, the mosquito is capable of transmitting the virus for the rest of its life [53].
After a mosquito bites a human, DENV is delivered into the dermis where it 
can infect/replicate in dendritic cells (DCs) (Langerhans cells) and keratinocytes 
residing in the basal and suprabasal layers of the epidermis [54–56] (Figure 2). 
Virus dissemination to the local lymph nodes occurs in association with infected 
migratory dendritic cells or as free viruses of the lymphatic fluid leading to vire-
mia [57]. At this stage, mosquito saliva has shown to enhance the replication and 
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pathogenesis of numerous arthropod-borne viruses, including DENV [58–62]. 
DENV infection cycle initiates with the virus attachment to the target cells [63]. 
The current model suggests that DENV uses both attachment factors and primary 
receptor(s) that facilitate virus recruitment on the cell surface, and later, inter-
nalization inside host cells via receptor-mediated endocytosis including clathrin-
mediated and nonclassical clathrin-independent endocytosis [64, 65]. Despite this, 
the single definitive receptor mediating this critical step in the DENV replication 
cycle continues to be elusive. So far, numerous candidates have been described in 
the mammalian and mosquito cells, including glycosaminoglycans such as hepa-
ran sulfate and lectins, the adhesion molecule of dendritic cells (DC-SIGN), the 
mannose receptor (MR) of macrophages, the lipopolysaccharide (LPS) receptor 
CD14, and stress-induced proteins such as the heat-shock proteins 70 and 90 and 
the endoplasmic reticulum (ER) chaperonin GRP78 [64–68]. This suggests that 
DENV may not use a unique, specific receptor to enter cells, but recognizes diverse 
molecules, both in the vertebrate and mosquito hosts, which can potentially explain 
the broad tissue range that defines DENV tropism and infection.
After the internalization of the virion, a fusion between the viral E protein 
and the endosomal membrane mediates the access of the viral genome into the 
cytoplasm [43, 65]. The E protein is a glycosylated viral protein and a member of 
class II viral membrane fusion protein family [43, 69]. The crystal structure of 
Figure 1. 
Dengue virus genome organization, NS1 structure, and dengue epidemiology and disease outcome. (A) 
Schematic representation of the DENV genome and polyprotein. Dengue virus (DENV; genus Flavivirus, 
family Flaviviridae) is a positive-sense, single-stranded (∼11-kb length), and RNA-enveloped virus with an 
icosahedral capsid protecting the virus genome, which is transmitted by mosquitoes of the Aedes genus (Aedes 
aegypti, Ae. albopictus) and affects more than 40% of the human population worldwide living in tropical 
and subtropical areas. The viral RNA genome poses one single open reading frame encoding for one single 
polyprotein, which after being processed by cellular and viral proteases generates three structural proteins 
known as the capsid (C), the membrane (M), and the envelope (E) and seven nonstructural (NS) proteins 
known as NS1, NS2A, NS2B, NS3, NS4A, NS4B, and N5. The viral RNA contains a cap in the 5′-end, and 
it has no poly-a tail in the 3′-end. Several secondary structures or UTRs (untranslated regions) are found 
in both ends which have been shown to participate in viral replication as well as host adaptation. Of the 
structural proteins, the envelope (E) is the major protein on the virion, which participates in cellular receptor 
recognition to infect the host cells and the main target for adaptive immune responses in humans. On the other 
hand, the NS proteins play critical roles in the virus replication cycle and the subversion of the host antiviral 
responses, particularly those triggered by the innate immune response against DENV infection. (B) Of these NS 
proteins, NS1 is the only viral protein secreted by DENV-infected cells in which the plasma circulating levels 
are increased during the acute phase of DENV-infected patients undergoing severe disease. The NS1 protein 
circulates as a lipoprotein-like particle with a hexameric conformational structure containing three domains 
termed as the wing domain (here in yellow), the β-ladder domain (in blue), and the β-roll domain (in red) 
(NS1 hexamer is depicted in this figure). NS1 has been demonstrated to play critical roles in the formation of 
new viral particles, the evasion of the immune system, and very recently, it was implicated in modulating the 
virus pathogenesis of DENV that is mainly associated to its potential role in acting as a pathogen-associated 
pattern molecule (PAMP) which activates the production of pro-inflammatory host soluble factors such as 
cytokines, chemokines, proteases, etc. from the immune cells and directly triggers the barrier dysfunction of 
endothelial cell cultures in vitro and vascular leak in the mouse models in vivo. Taking these together, NS1 is 
now considered as a viral toxin not only of the DENV complex but of many of the closely related flaviviruses, 
including ZIKV, WNV, and YFV among others. (C) The DENV complex is composed of four serologically but 
antigenically related types of viruses, known as DENV serotypes (1, 2, 3, and 4). The primary infection with 
any of the four serotypes often cause inapparent, asymptomatic, or mild diseases that prime the immune system 
for a long-life immunity against the infecting DENV serotype (here DENV-1, in yellow) which is dominated 
by homotypic immune responses at mostly all levels, including antibody-B cells’ and T cells’ responses. During 
secondary infections, things get more complicated as infection with a different DENV serotype as the one from 
the primary infection; here DENV-2 (blue), DENV-3 (red), and DENV-4 (green) results in cross-reactive 
and heterologous immune responses that are considered the main risk factor to develop severe manifestations of 
DENV infections, including dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS), which may 
lead to life-threatening health complications and sometimes, death. In the course of this chapter, we will explain 
how these epidemiological factors may be associated with the development of severe dengue disease that may 
be a consequence of a combined interplay set of immunopathogenic mechanisms triggered by the host immune 
response having DENV infection as the main trigger. The model of NS1 hexamer was built based on the crystal 
structure deposited in the Protein Data Bank (PDB4O6B). Molecular graphics were performed using the 
PyMOL molecular graphics.
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E glycoprotein ectodomain revealed three domains contributing to the β-barrel 
central structure of the protein (domain I, DI), permitting the fusion of viral and 
cellular membranes during virus entry (domain II, DII, and fusion loop), and a 
structural basis for immune recognition and cellular receptor binding (domain III, 
DIII) [43, 70]. The low pH of the endosomal compartment induces conformational 
changes in the E glycoprotein, which allows the fusion of the viral and host mem-
branes [43, 69]. This results in the release of the viral RNA genome into the cyto-
plasm. The single-stranded positive-sense RNA immediately acts as a messenger 
RNA, which can be subsequently translated by cellular machinery to generate viral 
polyproteins, subsequently processed by both cellular and viral proteases to gener-
ate mature viral proteins [69, 70]. In this stage, the nonstructural proteins have been 
shown to induce massive remodeling of ER membranes, manifesting as convoluted 
membranes and vesicle packets (VPs) to form a dynamic and membrane-bound 
multi-protein assembly, named the replication complex (RC) where the genome 
is replicated, and new viral RNA copies are incorporated into nascent particles 
[71, 72]. Viral RNA synthesis relies on NS5, the RNA-dependent RNA polymerase 
as well as on critical RNA secondary and tertiary structures [73–75]. NS3 is a 
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protease-helicase which together with its cofactor NS2B, participates in the pro-
cessing, efficient RNA synthesis, and capping of the viral polyprotein [72, 76, 77]. 
NS2A recruits nascent RNA as well as C-pre-M-E [78]. NS1 interacts with structural 
proteins and NS4A-2 K-4B to facilitate the production of infectious virus particles 
[11, 79]. Because of their critical roles in the DENV replication cycle, NS2B, NS3, 
and NS5 along with NS4B are the main focus to design new inhibitors for antiviral 
therapy against DENV and other related flaviviruses [80–83]. Assembled viruses 
are transported through the trans-Golgi network (TGN) where under acidic condi-
tions, a cellular protease, furin, cleaves pre-M, allowing full maturation of infec-
tious virions that will be finally released via exocytosis [84].
3. Dengue virus infection, epidemiology, and clinical features
Dengue is the arboviral infection with the highest disease incidence worldwide, 
with 2.5 billion people living in dengue-endemic tropical and subtropical regions 
[1, 85, 86]. In the last four decades, the geographical spread and intensity of dengue 
Figure 2. 
Dengue virus infection, pathogenesis, and immune responses in the skin. The skin represents the first line of 
defense of the human body against pathogens such as viruses, as it generates early immune responses, aiming 
to protect humans against cutaneous and systemic infection (1). The human skin constitutes a complex 
organ nicely structured in three escalated layers known as the epidermis, which is composed of closely packed 
epithelial cells including keratinocytes, melanocytes, and Langerhans cells (LCs), a specialized type of 
dendritic cell (DC) that constantly probes for antigen in the most exposed, superficial layer of the skin; the 
dermis, which is made of dense, irregular connective tissue, blood vessels, and other structures; and the inner 
hypodermis, which is composed mainly of loose connective and fatty tissues (2). Upon disturbance of the 
epidermal barrier by mosquito blood-feeding, DENV-infected mosquitoes inoculate newly generated infectious 
virus particles along with mosquito saliva in which a complex mixture of proteins that exerts profound effects 
in the human immune system allows the acquisition of the mosquito blood meal from its host by circumventing 
vasoconstriction, platelet aggregation, coagulation, and inflammation or hemostasis (3). In the skin, major 
constituents of the innate immune system include phagocytic cells such as macrophages, neutrophils, and DCs as 
well as innate leukocytes such as natural killer (NK) cells, mast cells (MCs), basophils, and eosinophils. Also, 
epidermal keratinocytes act as active innate immune cells. In response to sensing pathogen-associated molecular 
patterns (PAMPs) expressed by microbes and host danger molecules, innate immune receptors present on 
keratinocytes and APCs become activated, causing the release of inflammatory cytokines and antimicrobial 
peptides (4). At the site of inoculation in the skin, the key targets of DENV infection are immune cells of 
the myeloid lineage, including various subsets of DCs, monocytes/macrophages, and MCs (5). Despite this, 
limited virus particles are thought to be deposited in the epidermis during mosquito blood-feeding (3), and in 
that location, Langerhans cells as well as keratinocytes are considered target cells (6). In the dermis, DCs and 
monocytes/macrophages are also prime infection targets (7). MCs are not substantially infected in the skin (8). 
However, exposure to DENV triggers an augmented activation of MCs leading to degranulation and release of 
de novo-synthesized inflammatory and vasoactive mediators, including proteases, leukotrienes, and histamine 
that, along with some vasoactive molecules and maybe the secreted NS1 originated from infected mosquito 
cells in the salivary glands, promote edema within the site of infection as a consequence of the increased 
microvascular permeability (9). Activation of MCs also induces the secretion of cytokines and chemokines 
that leads to the recruitment of NK cells, neutrophils, and monocyte-derived dendritic cells (mDCs) to the 
site of infection (10). Already in the skin, mDCs can serve as targets of infection, allowing the amplification of 
the virus in the skin, while natural killer (NK) cells, natural killer T (NKT) cells, and CD8+ T cells can kill 
DENV-infected cells and promote virus clearance in a cellular cytotoxic-dependent manner (11). Once human 
skin is infected, DENV-infected DCs take virus into the draining lymph nodes using afferent lymphatic vessels 
where they spread DENV infection and most importantly activate antigen-specific CD4+ and CD8+ T cells 
which initiates the adaptive immune response (12, 13). In the T cell zones, activated T cells become effectors cells 
to promote the development of DENV-specific memory B cells and plasma cells in the germinal center of LN. 
Activated T cells can reenter circulation and potentially return to the skin for virus clearance during subsequent 
DENV infections, playing an important role in protecting against DENV (14). In the skin, in addition to the 
mosquito saliva, DENV infection of target cells such as DCs, monocytes/macrophages, and MCs can be also 
modulated by the presence of preexisting antibody responses against previous infections with distinct DENV 
serotypes or other closely related flaviviruses, in an antibody-dependent enhancement (ADE) manner (See 
DENV-ADE in Part II for more details). For MCs and DCs, DENV-ADE is possible through Fc-γ-receptors 
(FcγRs). Besides, MCs degranulation can be enhanced through cross-linking of FcεRs when bound to DENV-
specific IgE, leading to augmented MC activation and presumably immune-mediated vascular injury (15). 
After skin infection, DENV must achieve systemic infection to complete its transmission cycle by infecting 
new mosquito hosts. Infection of secondary LNs following infection of the draining LN are considered the 
amplification centers for DENV that contributes to the systemic infection and virus transmission (16).
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have grown dramatically around the world accompanied by the wide distribution of 
the two main vector mosquitoes, Aedes aegypti and Aedes albopictus, which today are 
fully adapted to human dwellings creating new opportunities not only for DENV 
but also for other arthropod-transmitted viruses (arboviruses) transmission, such 
as Zika virus (ZIKV) and chikungunya virus (CHIKV), within human populations. 
These features along with the continuous growing of urbanization, globalization, 
and the lack of effective mosquito control represent some of the critical factors 
that have contributed to the emergence and reemergence of mosquito-transmitted 
viruses around the world [48, 87, 88].
Infection with any of the four DENV serotypes results in a diverse range of 
symptoms going from mild undifferentiated fever to life-threatening manifesta-
tions, which are characterized by increased vascular permeability, hemorrhage, and 
shock [89] (Figure 1C). In 1997, the World Health Organization (WHO) classified 
symptomatic DENV infections into three categories and subcategories known as 
dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome 
(DSS). After an incubation period of 3–7 days, symptoms start suddenly and follow 
three phases: an initial febrile phase, a critical phase around the time of deferves-
cence, and a spontaneous recovery phase [89]. Classical DF is an incapacitating 
disease that affects older children, adolescents, and adults, mainly characterized 
by the abrupt onset of fever (up to 40°C) and severe headache, accompanied by 
retro-orbital pain, myalgia, arthralgia, gastrointestinal discomfort, and transient 
rash [89]. In turn, DHF and DSS can rapidly deteriorate, progressing to hemorrhage 
with or without vascular leak after an early acute-onset febrile period, particularly 
during defervescence, where the symptoms are similar to those presented during 
classical DF. DHF and DSS are classified into four subcategories or grades (I–IV), 
where grades I and II (DHF) are represented by mild cases presenting some 
bleeding manifestations without shock (petechiae, purpura, ecchymosis, bruis-
ing, epistaxis, etc.), whereas III and IV (DSS) are more severe and accompanied 
by severe hemorrhagic manifestations and thrombocytopenia (platelets counts: 
<100,000 platelets/μL) and evidence of increased vascular permeability (ascites, 
pleural effusion, increased hematocrit concentrations, and severe abdominal pain) 
during a critical period, sometimes accompanied with a profound and prolonged 
shock that potentially leads to death [90]. In this critical stage, liver failure, myo-
carditis, and encephalopathy often occur with minimal associated plasma leakage 
[89]. In 2009, the WHO revised the classification system for dengue and established 
new guidelines that replaced the more complicated dengue fever/dengue hemor-
rhagic fever (DF/DHF) system to separate patients enduring severe disease from 
those with non-severe manifestations. This new guideline defined two new major 
entities—dengue and severe dengue—which encompasses a set of “warning signs” 
intended to help clinicians identify the patients likely to develop complications 
during the critical phase of the illness [89].
Currently, there is no effective and safe vaccine or FDA-approved specific antiviral 
drug options to combat dengue disease, with treatment being purely supportive [91]. 
Prevention or reduction of DENV transmission by implementing combined effec-
tive control strategies remains as the primary approach to be used to prevent DENV 
transmission within human populations [92]. With the majority of DENV infections 
being asymptomatic (70–80%), and most symptomatic infections not progressing to 
severe disease [3], the global distribution of dengue remains highly uncertain as the 
actual numbers of dengue cases are underreported and many cases are misclassified. 
One recent study estimate indicates that 390 million DENV infections occur annually 
with more than 500,000 cases of hospitalizations and more than 25,000 deaths (2.5% 
case fatality, annually) [1]. A different study estimated that 3.9 billion people living 
in 128 countries are at risk of being infected with dengue viruses [85]. These studies 
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demonstrate the worldwide expansion of the dengue disease and the establishment of 
an increasingly important infectious disease of global public health significance.
4.  Dengue immunopathogenesis and severe disease: host and viral 
factors
The hallmark of severe dengue is the transient perturbation in the integrity of 
the endothelium lining the inner side of blood vessels as well as the alteration in the 
coagulation cascade leading to shock and severe hemorrhage manifestations [9, 89]. 
Increased vascular permeability in severe dengue results in decreased circulating 
plasma volume, haemoconcentration, and pleural and peritoneal effusions that 
result in severe life-threatening shock [93–96]. Numerous epidemiological pieces 
of evidence indicate that appearance of the life-threatening manifestations dur-
ing severe dengue occurs shortly after the defervescence stage of dengue disease, 
when the peak of viremia passed, meaning that host innate and adaptive immune 
responses have cleared the virus from host tissues [97, 98]. At this time, a transient 
vascular leakage pathology is observed followed by a rapid recovery in association 
with the late febrile phase. This association led to the suggestion that the key biolog-
ical mechanisms such as alterations on the vasculature that leads to the pathogenesis 
of clinical complications during DENV infection are rather functional than the 
structural changes in the endothelium and are primarily a consequence of short-
lived biological mediators closely linked to the host immune responses [93–96].
Although many severe infections occur upon secondary encounters with heterolo-
gous DENV serotypes [9, 99], suggesting an immune-mediated process is involved, 
the multifactorial immunopathogenic process of DENV infection implies a complex 
interaction between distinct viral and host processes that sometimes leads to increased 
virus infection, exacerbated immune responses, and the appearance of life-threat-
ening severe manifestations such as severe plasma leakage, hemorrhage, and organ 
failure. Higher virus pathogenicity (virulence), preexisting serotype cross-reactive 
antibodies, activation of DENV-infected immune cells [e.g., monocytes and mast cells 
(MCs)], T cell responses, activation of complement pathways, the potential infec-
tion of endothelial cells, and the new pathogenic roles of the secreted NS1 of DENV 
may work synergistically to induce the release of vasoactive cytokines which results 
in increased endothelial permeability causing vascular leakage and pleural effusion, 
which are still considered pathognomonic features of severe dengue that leads occa-
sionally to shock and death [8, 9, 35, , 96, 99–110]. In this section, we highlight in two 
parts I and II, the immunological events elicited by DENV infection, which have been 
suggested to play a key role in the development of severe dengue manifestations.
4.1 Dengue virus tropism and infection of immune cells
Numerous in vitro studies have shown that DENV is able to infect a variety of cell 
types including epithelial cells, endothelial cells, hepatocytes, muscle cells, dendritic 
cells, monocytes, B cells, and mast cells [65, 66, 111–117]. Several autopsies and ex vivo 
studies have found the presence of DENV antigens (e.g., envelope protein, NS3) in some 
tissues such as the skin, liver, spleen, lymph node, kidney, bone marrow, lung, thymus, 
and brain [56, 67, 68, 118–122]. However, infectious virus particles have not always been 
isolated from all these organs but only from the liver and peripheral blood mononuclear 
cells (PBMCs), suggesting that: (a) the presence of DENV antigens such as the structural 
proteins E, pre-M, and C in several organs may not always be associated with the evi-
dence of productive viral infection and severe organ pathology and (b) the immune cells 
and liver may be the main targets for DENV replication during the dengue disease [67]. 
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In animal models such as the alpha/beta (IFN-α/β)-deficient mice (Ifnar−/−) and 
nonhuman primates, DENV has been recovered from the spleen, liver, peripheral 
lymph nodes, and the central nervous system [123–127]. However, the absence of an 
appropriate animal disease model has largely hampered with the understanding of the 
role played by DENV tropism in vivo. Sustained viral replication and severe manifesta-
tions have been observed in Ifnar−/− mice after infection with DENV, which gives a clear 
advantage to study DENV pathogenesis in vivo, but the absence of intact IFN signaling 
is a limitation that must be considered when interpreting data [128].
The fact that DENV can infect many mammalian and insect cell types in vitro 
and in vivo suggest there are different molecules or cellular routes that might be 
controlling virus attachment and internalization, resulting in productive infec-
tion [63]. Numerous studies have shown that C-type lectins including DC-SIGN 
(CD209) and C-type lectin domain family 5, member A (CLEC5A) expressed on 
dendritic cells and macrophages act as cellular receptors for DENV [129–131]. 
Other extensively studied DC receptors are the mannose receptor (MR), Langerins, 
Fc-receptors, TIM3, TIM4, and AXL [63, 65, 132, 133]. Contrary to the DC-SIGN 
that may primarily function as a viral attachment factor, DENV binding to CLEC5A 
(C-type lectin domain family 5, member A), highly expressed by monocytes, mac-
rophages, neutrophils, and dendritic cells, has been shown to induce the production 
of antiviral and pro-inflammatory cytokines suggesting that this C-type lectin may 
act as a cognate receptor for dengue virion [131, 134]. These cytokines include type 
I IFNs and chemotactic factors such as migration inhibition factor (MIF), monocyte 
chemotactic factor (MCP), and IL-8 [102, 134]. DENV infection of DCs also induces 
the production of matrix metalloproteinases (MPPs), MMP-2 and MMP-9, which 
induces migration of DCs to lymph nodes where virus further replicates before it 
disseminates into the blood circulation [135]. In the skin, DENV also infects mast 
cells that can be activated leading to degranulation and increased secretion of vari-
ous inflammatory cytokines (IL-1, IL-6, TNF-α, and IFN-α), chemokines (CCL5, 
CXCL12, and CX3CL1), and chymase, the latter being a protease found circulating 
at high levels in the blood of dengue patients, suggesting a potential role in the 
development of severe dengue that contributes to vascular leakage [115, 136–140]. 
All these innate immune processes together lead to an antiviral state in nearby cells, 
generating an inflammatory response and recruitment of natural killer (NK) cells to 
combat DENV infection [54, 141].
Along with DCs, monocytes and macrophages are also the primary targets of 
DENV infection [142, 143]. In lymphoid and nonlymphoid tissues, macrophages 
are considered the primary reservoirs of DENV after its dissemination from the 
skin [144]. Macrophages susceptible to DENV have been found in different organs 
in the mouse models or human autopsies, namely, Kupfer cells in the liver, alveolar 
macrophages in the lungs, dermal macrophages, microglial cells (brain and spinal 
cord), and monocytes in the peripheral blood [118, 120, 122, 145–147]. Comparable 
to DENV infection of DCs, DENV can use an array of cell surface receptors to 
infect monocytes and macrophages, including mannose receptor (CD205), CD14-
associated protein, heat shock proteins (HSP70/HSP90), DC-SIGN (CD209), 
CD300a, AXL, TIM4, PD1, and the Fc receptors, particularly FcγRI (CD64) and 
FcγRII (CD32, 63). These two Fc-Rs play major roles in enhancing DENV infection 
of monocytes and macrophages, particularly during secondary infections [148–151].
Other populations of immune cells including NK cells can also be activated dur-
ing DENV infection, particularly in patients with DHF compared to those with DF 
[141, 152, 153]. Additionally, B cells and T cells have been studied to test permissive-
ness to DENV, but these studies have resulted in contradictory results [154–156]. 
In vitro studies using B cell and T cell lines (e.g., Raji cells, Daudi, and Jurkat) and 
primary B cells derived from healthy human peripheral blood mononuclear cells 
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(PBMCs) have revealed the potential role of these cells in DENV replication, both 
in presence and absence of heterologous antibodies [67, 155, 157–159]. Additional 
studies using a humanized mouse model found that DENV infected both B and T 
cells accompanied by an important production of pro-inflammatory cytokines such 
as IL-6 and TNF-α, like monocytes and macrophages [160]. Despite this evidence, 
the role of lymphoid cells such as B and T cells in DENV tropism and replication 
needs further exploration.
4.2 DENV infection and the host innate immune responses
Although plasma leakage in severe dengue occurs at the end of the acute illness, 
there is substantial evidence that the pathophysiologic processes start at the earliest 
stages of DENV infection [95, 96]. Introduction of DENV particles along with mosquito 
saliva triggers a variety of host innate immune responses leading to the production 
of antiviral and pro-inflammatory cytokines mostly from the immune cells exposed 
to DENV [57, 62, 138]. At this stage, innate immune cells are the first to respond to 
infection through stimulation of patterns recognition receptors (PRRs) recognizing 
pathogen-associated molecular patterns (PAMPs) as well as endogenous molecules 
released from damaged cells, termed damage-associated molecular patterns (DAMPs) 
[161, 162]. PRR recognition triggers the production of cytokines and chemokines, 
which induces a local antiviral state [54, 55]. This local innate response could potentially 
play an important role in modulating local viremia and virus dissemination by recruit-
ing susceptible target cells for DENV infection at the inoculation site [57, 62, 144].
PRRs include transmembrane proteins such as the Toll-like receptors (TLRs) and 
C-type lectin receptors (CLRs) as well as cytoplasmic proteins such as the retinoic 
acid-inducible gene (RIG)-I-like receptors (RLRs) and NOD-like receptors (NLRs) 
[161]. These are an essential part of the innate immune response against the virus, 
sensing viral replication in the cytoplasm [161, 163]. The PRRs that are associated with 
DENV recognition after infecting target cells are the cytoplasmic retinoic acid-induc-
ible gene I (RIG-I) and the melanoma differentiation-associated protein 5 (MDA5) and 
the endosomal Toll-like receptor 3 (TLR3) and TLR7 [164–166]. Recognition of DENV 
RNA by TLR-3 results in the production of type I IFN and chemokines such as IL-8 via 
sensing of phosphate-containing RNA and long double-stranded RNA (dsRNA) in the 
cytoplasm or inside endosomal compartments [167, 168]. DENV infection in nonhu-
man primates demonstrated that the administration of TLR-3 and TLR7 agonists 
resulted in significantly decreased viral replication and increased production of 
pro-inflammatory chemokines as well as increased production of antibodies targeting 
DENV [169], indicating a protective role for TLRs during DENV infection.
Additional pathways such as the cyclic GMP-AM synthase (cGAS), a DNA-sensor 
pathway which triggers the simulator of IFN genes (STING) pathway are also acti-
vated during DENV infection leading to the production of type I IFN and activation 
of TLRs (TLR9), an endosomal PRR that recognizes cytoplasmic DNA originated 
from mitochondrial damage [170–172]. In addition to type I IFN production, small 
RNAs such as micro RNAs (miRNA) and the complement system are important 
components of the innate immune response against viral infections [173, 174]. miR-
NAs are processed by and interact with the proteins in the RNA interference (RNAi) 
pathway, such as Dicer, Drosha, Argo1, and Argo2 [175]. RNA interference (RNAi) is 
an important antiviral defense response in plants and invertebrates [176]. In DENV 
infection, knockdown of these components resulted in increased DENV replication 
in mammalian cells, suggesting that the RNAi pathways may play important roles 
in the cellular anti-DENV responses [177, 178]. Additional evidence showed that 
DENV can interfere with RNAi pathways in human hepatocytes cells via NS4B and 
subgenomic flavivirus RNA (sfRNA) interactions with Dicer’s ability to process small 
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RNA in vitro [179]. sfRANs are abundant noncoding RNA sequences derived from 
the stalling of the host 5′-3′ exoribonuclease XRN1/Pacman in the 3′-untranslated 
regions (3′UTRs) of the viral genomic RNA [180]. sfRNAs have been shown to block 
exonuclease XRN1, increasing the overall messenger RNA stability within the host 
cell which may also benefit the viral RNA [181–183]. However, evidence for RNAi 
contribution to mammalian antiviral defense are few and still controversial [179]. 
miRNAs have been shown to regulate TLRs and IL-1 signaling pathways in response to 
viral infection, which provides control of host innate immune responses [184]. So far, 
there have been reported several cellular miRNAs (miRNAome) that are modulated 
during DENV infection of mammalian cells, mainly related to the regulation of IFN-β 
signaling pathways [185–188]. Some of these miRNAs have been proposed to be used 
as biomarkers in dengue-infected patients [189, 190]. Interestingly, modulation of 
microRNA expressions have been also described upon DENV infection of insect cells 
(e.g., C6/36 cells) as well as adult vector mosquitoes such as Aedes albopictus [191–193], 
suggesting that DENV might also regulate the activation of these antiviral RNAi 
pathways in vector mosquitoes, potentially avoiding viral clearance that promotes 
viral replication and transmission [194]. Despite RNAi constituting an evolutionarily 
conserved phenomenon of the mosquito-innate immune response to virus infections 
[195], viruses have found ways to subvert the RNAi-mediated antiviral responses in 
vector mosquitoes to manipulate miRNA profiles to their own benefit [196].
Regarding the complement system, this multifaceted pathway has been shown 
to limit DENV replication; however, excessively activated complement components 
have been also associated with disease severity [197]. The complement cascade 
constitutes an integral component of the immune system, composed of many 
plasma proteins that once activated can initiate a proteolytic cascade, resulting in 
the release of chemokines, facilitation of particle phagocytosis via opsonization, 
and deposition of the cell-killing membrane attack complex (MAC) designed 
to target and destroy foreign pathogens such as viruses [174]. Activation of the 
complement system occurs via three convergent pathways: the classical, the lectin, 
and the alternative pathways [174]. In vitro experiments showed that DENV replica-
tion enhances complement activation [197–199]. Additionally, clinical and in vivo 
studies have shown that excessive consumption of some complement components 
(e.g., C3, C4, and factor B) contributed to severe manifestations by increasing the 
levels of complement-activated products which enhance vascular permeability 
to cause severe dengue disease [9, 108, 109, 200]. In fact, increased circulation of 
anaphylatoxins (C3a, C4a, and C5a) in the blood of severe patients correlated with 
symptoms of vascular leakage [109, 200]. In autopsy studies from children who 
died of acute severe dengue manifestations (DHF/DSS), augmented deposition of 
complement components from both classical and alternative pathways were found 
on hepatocytes which results in severe liver damage and death [120]. Altogether, 
these data support the hypothesis that exacerbated complement activation influ-
ences dengue disease immunopathogenesis leading to disease severity [197].
4.3 DENV subversion of antiviral responses
The first barrier to overcome for successful viral infection is the rapid innate 
immune responses of the host, including type I IFNs, inflammatory cytokines, 
complement responses, NK cells, apoptosis, and autophagy [201, 202]. These innate 
immune responses are meant to defeat viral infections by engaging specific viral 
components (e.g., RNA and DNA) leading to activation of immediate protective 
defense mechanisms such as the rapid recognition of PAMP in nonimmune and 
innate immune cells [161]. IFN production is a key goal of PRR activation for viral 
pathogens, and DENV is highly susceptible to effective induction of both type 
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I (IFN α/β) and type II (IFN γ) interferons [124, 203, 204]. Accordingly, in vivo 
DENV infection of wild-type mice causes little disease; in contrast, in mice lacking 
of type I IFN receptors (IFANR), DENV infection causes mortality [126].
Secreted type I IFNs trigger autocrine and paracrine induction of cellular antiviral 
responses and warning signals to noninfected adjacent cells, such as the expression 
of the interferon stimulated genes (ISGs) [205, 206]. ISGs have been shown to exert 
numerous antiviral effector functions, many of which are still not fully described 
[207]. Upon DENV infection, RLRs are activated to trigger antiviral responses based 
on the induction of type I IFN and pro-inflammatory cytokines [208]. The binding 
of type I IFN with its receptor activates multi-subsets of ISGs through JAK-STAT 
signaling which amplifies and sustains the initial antiviral responses [207, 209, 210]. 
However, ISGs can also be activated in IFN-independent pathways during DENV 
infection [211]. DENV infection has been shown to trigger the transcriptional activa-
tion of ISGs in vivo and in vitro [208, 212–215]. For instance, a tripartite motif (TRIM) 
protein encoding gene, TRIM69, is induced during DENV infection as an ISG. TRIM69 
restricts DENV replication by direct interaction with DENV NS3, which mediates its 
polyubiquitination and degradation in a process called ISGylation [216]. In addition 
to ISGs, activation of the transcription factors IRF-3, IRF-7, and NF-κB through either 
the TLR or RIG-I/MDA5 pathways results in the production of type I IFN which con-
tributes to anti-DENV immunity [217, 218]. IRF-3 and IRF-7 are part of the interferon 
regulatory factors (IRFs) considered the master regulators of the type I IFN produc-
tion that contribute to the suppression of viruses [219]. Due to the central importance 
in viral defense, many pathogenic viruses, including DENV, have evolved mechanisms 
to suppress IRF signaling. In the case of DENV, the nonstructural proteins restrict 
IRF3 and IFN response which facilitate DENV replication and virulence [220].
In recent years, considerable advances have been made toward understanding of 
the specific IFN antagonistic mechanisms evolved by DENV to subvert these intracel-
lular antiviral mechanisms and directly inhibiting these cellular signaling cascades, 
which results in enhanced virus infection, pathogenesis, and disease [167, 221]. This 
is supported by the increased susceptibility of mice deficient in IFN-α/β and IFN-γ 
receptors (AG129) to DENV infection as compared to wild-type mice [124, 126, 127]. 
Although IFN response is antagonized in mouse, human cells still induce high levels 
of IFN production in response to DENV, so this pathway is not entirely abrogated in 
humans during infection [203, 222]. Accordingly, humans infected with DENV have 
high levels of circulating of type I and type II IFNs [223–225]. Strong IFN-α responses 
have shown to correlate with milder dengue clinical conditions [226]. Similarly, the 
levels of the dengue-related gene expression of ISGs have been reported to be lower in 
patients with more severe disease [227–229] suggesting that DENV may abrogate IFN 
responses to facilitate viral infection which results in severe manifestations.
From the viral perspective, DENV uses its nonstructural (NS) proteins to block and 
inhibit the antiviral sensing pathways in infected cells. NS2a, NS3, NS4a, NS4b, and NS5 
prevent the virus from being sensed by RIG-I, inhibiting IFNβ induction [230–233]. 
NS2a, NS4a, and NS4b complex inhibits STAT1 signaling after IFNAR activation in vitro 
[233, 234]. NS5 induces proteasomal degradation of STAT2 which inhibits IFN-mediated 
response [230]. NS2b induces degradation of cGAS, which prevents DNA sensing result-
ing from mitochondrial damage [170, 171, 235]. The NS2b/3 protease complex cleaves 
STING which inhibits IFN production [236]. This phenomenon has been shown to 
occur in human but not nonhuman primates, suggesting that DENV may have evolved 
to increase viral titers in human populations, while maintaining decreased titers and 
pathogenicity in rare animals would serve as a sustainable reservoir in nature [237].
In addition to NS proteins, flavivirus sfRNAs have been described to regulate the 
innate immune responses via binding and inactivating RNA-binding proteins which 
are crucial for innate immunity [180, 238]. DENV 3′UTRs possess RNA structures 
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necessary for viral genome cyclization, viral RNA synthesis, translation, and repli-
cation [239]. sfRNAs regulate the pathogenicity in both mammalian and mosquito 
cells after interacting with proteins such as TRIM25 to inhibit RIG-I signaling and 
translation of ISGs [73, 240, 241]. Interestingly, reduced IFN responses have been 
found during DENV outbreaks where the infecting DENV serotype produced 
greater levels of sfRNA than the less pathogenic strains [100, 240]. Thus, high levels 
of sfRNAs may cause an epidemiological fitness of DENV, which results in lower 
stimulation of RIG-IMDA5 RNA sensors and reduced production of IFN, causing 
higher viremia levels that could be translated in more infections and severe diseases.
On the other hand, DENV utilizes the endoplasmic reticulum (ER) of host cells for 
replication and assembly. In this process, the ER undergoes extensive rearrangements 
and expansion that requires de novo synthesis of viral proteins [71]. Accumulation of 
unfolded proteins in the ER lumen leads to an unfolded protein response (UPR), a 
pro-survival cellular reaction induced in response to DENV-mediated ER stress  
[242, 243]. DENV has evolved to manipulate the UPR to cope with ER stress which 
hijacks the host cell machinery to evade the host immunity, facilitating viral replica-
tion [112]. Distinct in vitro and in vivo studies have shown that DENV induced ER 
stress and manipulates the host metabolism and protein production by increasing 
the autophagy (lipophagy) activity, viral replication, and pathogenesis through UPR 
signaling pathways [244–247]. Autophagy is the lysosomal degradation of cytoplas-
mic contents, which results in the recycling of cellular macromolecules as well as the 
activation of cellular host responses to starvation or stress [248]. Autophagy has been 
implicated as an innate immune response that would engulf and destroy pathogens 
by degrading cytosolic contents [249, 250]. In DENV infection, functional autophagy 
components have been shown to either promote or restrict viral RNA replication and 
virus production [251–253]. However, DENV has found ways of preventing autopha-
gic processing and degradation of viral components [254, 255]. Several studies have 
linked DENV induction of autophagy to the regulation of lipid metabolism, leading to 
increased degradation of lipid droplets that produces more fatty acid material impor-
tant for viral replication [247]. In this process, the NS3, NS1, and C proteins of DENV 
have been found to increase fatty acid biosynthesis and recruitment of lipid droplets 
to the DENV replication complex, facilitating viral particle assembly [256, 257].
Furthermore, several studies have shown that lipids and lipoproteins play a role 
in modifying DENV infectivity in both mammal and insect cells in vitro [258, 259]. 
Modulation of cholesterol levels in the host cells facilitates viral entry, replication, 
virus assembly, and control type I IFN response [260, 261]. This modulation involves 
the regulation of cholesterol levels, expression of cholesterol receptors as well as 
changes in cholesterol synthesis related to important modifications in the cellular 
metabolism [114, 262, 263]. Interestingly, clinical studies have found that levels of 
total serum cholesterol and LDL-C levels are modulated over the course of dengue ill-
ness, with generally lower levels associated with increased dengue severity [264–266]. 
In general, low cholesterol levels have been associated with critical illness related to 
sepsis and vascular disorders [267]. Thus, the association of cholesterol with severe 
dengue outcome may be an important indicator of the pathophysiology of DHF/DSS.
About the complement pathway, DENV has evolved strategies to limit recogni-
tion and activation of the complement cascade [108, 165]. NS1 is the only flavivirus 
protein that is secreted by infected cells and has been shown to modulate the comple-
ment pathway [14, 268]. NS1 promotes efficient degradation of C4 to C4b to protect 
DENV from complement-dependent neutralization [13, 269]. The NS1 protein of 
DENV and other flaviviruses such as WNV NS1 interacts with some components of 
the alternative complement pathway such as the C3bBb convertase, which limits the 
formation of C5b-9 membrane attack complex (MAC) [268, 270]. Additional studies 
have found that NS1 proteins from DENV, WNV, and YFV all attenuate classical and 
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lectin pathway activation by directly interacting with C4, which reduces C4b deposi-
tion and C3 convertase (C4b2a) activity [13, 271]. Also, anti-NS1 antibodies have been 
shown to induce complement consumption and C5b-9 generation [272]. Overall, 
through protein-to-protein interactions between the viral and host factors involved in 
antiviral responses and careful manipulation of cellular processes, such as ER expan-
sion, autophagy and lipid metabolism, and complement pathways, DENV hijacks 
many host antiviral responses to facilitate virus replication leading to pathogenesis.
5. Concluding remarks (Part I)
Dengue is the most prevalent arboviral disease transmitted by mosquitoes, which 
poses an enormous burden to the public health systems worldwide as more than 40% 
of the world population is at risk of infection. The infection with any of the four 
DENV serotypes (DENV1–4) can lead to a wide spectrum of clinical manifestations 
that range from the asymptomatic or inapparent to moderate flu-like symptoms, 
known as dengue fever (DF), and life-threatening manifestations identified by the 
WHO, known as the dengue hemorrhagic fever and dengue shock syndrome (DHF/
DSS), also known as severe dengue, with or without warning signs. In endemic areas 
where multiple DENV serotypes can seasonally circulate, distinct epidemiologi-
cal studies have demonstrated that an individual human being can be exposed to 
sequential infections with distinct DENV serotypes, which poses a risk of developing 
severe manifestations such as DHF/DSS. This phenomenon has been attributed to the 
potential enhancement activity that the preexisting antibody response elicited from a 
previous infection with one serotype (e.g., DENV-1) may have on the infection with 
a different serotype (e.g., DENV-2). This process leads to an increased viral burden 
that triggers a series of immunological and cellular events (e.g., ADE, cytokine 
storm, skewed T cell responses, and complement pathways), which despite being 
intended to prevent the invasion and infection of the infecting viral pathogens, can 
induce host tissue damage leading to pathology and disease. The cellular and molecu-
lar mechanisms involved in this phenomenon will be explained in more detail in the 
Part II of this chapter entitled “Adaptive immune response and NS1 pathogenesis.”
As an arthropod-transmitted virus (arbovirus), DENV is initially transmitted 
by an infected vector mosquito in which the virus has already been amplified after 
replication in its distinct tissues, starting at the midgut to finalize in the salivary 
glands, where a new transmission cycle begins after blood feeding from a new host 
(Figure 2). Following inoculation from the bite of an infected mosquito, viruses 
undergo replication in the local tissues such as the skin. In the skin, infectious virus 
particles along with mosquito saliva components including proteases and immuno-
modulatory proteins among others are sown in the epidermis and dermis, leading to 
an activation of a cascade of events including the recruitment of skin resident cells 
(e.g., Langerhans cells, mast cells, and keratinocytes) and new cells (e.g., T cells 
and neutrophils) into the site of the infection that later serve as viral targets for viral 
replication. After infection of target cells, sensing of viral products (e.g., PAMPs and 
DAMPs) results in the activation of innate immune responses (e.g., type I IFN chemo-
kines), the first line of defense, which establishes inflammatory and antiviral states 
intended to prevent the virus to colonize and to replicate in the skin; however, DENV 
has elaborated several pathogenic mechanisms to hijack these responses and escape 
from the normal immune system processing, which results in its dissemination and 
seeds into the lymph nodes. There, DENV further replicates in monocyte lineage cells, 
resulting in a primary viremia after its systemic dissemination through the circula-
tory bloodstream, which results in the subsequent infection of peripheral tissues such 
as the liver, spleen, and kidney. Overall, the skin represents not only the first line of 
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defense against arboviruses but also the main place where viruses have learned to 
evade the host immune responses leading to invasion and dissemination toward the 
establishment of systemic host infection, which will potentially assure subsequent 
virus transmission into a new host. In this Part I of the chapter entitled “Dengue 
virus tropism, host innate immune responses, and subversion of antiviral responses,” 
we discussed the distinct features of DENV as well as the biological and molecular 
mechanisms that can tilt the balance to either a local viral infection and dissemination 
through the skin or to the control and prevention of viral infection by the innate and 
adaptive immune responses at the site of the infection. Thus, the immunopathogenesis 
of arboviruses such as DENV in the skin is a critical step and must be a focus of future 
studies intended to reduce/block arthropod-borne transmission into humans.
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